New approaches to triglyceride reduction: Is there any hope left?

In March of 2023, a phase 2 trial in subjects with severe HTG failed to achieve significance in the prespecified primary endpoint of percent change in mean TG.

also in 299 other papers

In subgroup analyses, this was shown to be driven by the secondary prevention cohort, with a significant 19 % relative risk reduction (p=0.048), as the effect on the primary prevention cohort did not reach statistical significance.

also in 111,027 other papers